NuCana (NCNA) Cash from Operations (2017 - 2025)
NuCana (NCNA) reported Cash from Operations of 1529691.13 for Q4 2025, up 84.01% on a YoY basis from 831293.92 in Q4 2024, and down 188.7% sequentially from 1724484.82 in Q3 2025.
NuCana (NCNA) Cash from Operations (2017 - 2025) Analysis & Trends
NuCana (NCNA) has 9 years of Cash from Operations data on file, last reported at 1529691.13 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Operations rose 84.01% year-over-year to 1529691.13; the trailing twelve-month figure through Dec 2025 stood at 15354391.18 (up 37.32% YoY), and the FY2025 full-year result was 9845316.68, up 59.71% from the prior year.
- Cash from Operations fell to 1529691.13 in Q4 2025, from 1724484.82 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 1724484.82 in Q3 2025 to a low of 26927859.89 in Q4 2021.
- A 5-year average of 7832968.04 and a median of 7392209.14 in 2023 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations jumped 237.42% in 2022 and sank 9912.18% in 2024, its largest moves.
- Tracing NCNA's Cash from Operations over 5 years: stood at 26927859.89 in 2021, then jumped by 39.0% to 16425688.21 in 2022, then jumped by 99.42% to 95568.7 in 2023, then slumped by 9912.18% to 9568506.21 in 2024, then surged by 84.01% to 1529691.13 in 2025.
- Business Quant data shows NCNA's Cash from Operations at 1529691.13 in Q4 2025, 1724484.82 in Q3 2025, and 9568506.21 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 70.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.53 Mn |
| Dec 31, 2025 | -1.53 Mn |
| Sep 30, 2025 | 1.72 Mn |
| Sep 30, 2025 | 1.72 Mn |
| Dec 31, 2024 | -9.57 Mn |
| Dec 31, 2024 | -9.57 Mn |
| Sep 30, 2024 | -5.98 Mn |
| Sep 30, 2024 | -5.98 Mn |
| Jun 30, 2024 | -1.49 Mn |
| Jun 30, 2024 | -1.49 Mn |
| Mar 31, 2024 | -7.46 Mn |
| Mar 31, 2024 | -7.46 Mn |
| Dec 31, 2023 | -95,568.70 |
| Dec 31, 2023 | -95,568.70 |
| Sep 30, 2023 | -12.89 Mn |
| Sep 30, 2023 | -12.89 Mn |
| Jun 30, 2023 | -7.32 Mn |
| Jun 30, 2023 | -7.32 Mn |
| Mar 31, 2023 | -12.56 Mn |
| Mar 31, 2023 | -12.56 Mn |